Aurinia Pharmaceuticals (AUPH) reported a Q1 earnings Monday of $0.16 per diluted share, swinging from a loss of $0.07 a year earlier.
An analyst polled by FactSet expected EPS of $0.14.
Revenue for the quarter ended March 31 was $62.5 million, compared with $50.3 million a year earlier.
Analysts surveyed by FactSet expected $61.1 million.
For 2025, the company reiterated its total revenue guidance in the range of $250 million to $260 million. Analysts surveyed by FactSet expect $258.5 million.
Shares of the company rose 2.5% in recent premarket activity.
Price: 8.20, Change: +0.20, Percent Change: +2.50
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。